Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
, 10 (5), 719-25

Long-Term Recurrence Rates of Peptic Ulcers Without Helicobacter Pylori

Affiliations
Multicenter Study

Long-Term Recurrence Rates of Peptic Ulcers Without Helicobacter Pylori

Jae Hyun Seo et al. Gut Liver.

Abstract

Background/aims: The purpose of this study is to investigate the recurrence rate of peptic ulcer disease (PUD) over a long follow-up period with PUD patients without Helicobacter pylori.

Methods: We retrospectively reviewed patients diagnosed with PUD on endoscopy and divided them into two groups: a H. pylori-negative group (HP-negative group), and a group of patients with untreated H. pylori (HP noneradicated group). We compared the recurrence rates of PUD in these two groups and analyzed the factors that affected ulcer recurrence.

Results: Total of nine hospitals in Korea participated, and a total of 1,761 patients were retrospectively reviewed. The HP-negative group included 553 patients, and the HP noneradicated group included 372 patients. The 5-year cumulative probabilities of PUD recurrence were 36.4% in the HP-negative group and 43.8% in the HP noneradicated group (p=0.113). The factors that were found to affect recurrence in the HP-negative group were elder, male, and comorbid chronic kidney disease.

Conclusions: The 5-year cumulative probability of PUD recurrence without H. pylori infection after a long-term follow-up was 36.4% and the factors that affected recurrence were elder, male, and comorbid chronic kidney disease.

Keywords: Helicobacter negative; Natural course; Peptic ulcer disease.

Figures

Fig. 1
Fig. 1
Kaplan-Meier estimates of the 5-year cumulative probabilities (95% confidence interval) and comparison of the recurrence of peptic ulcers in the two groups using a log-rank test.

Similar articles

See all similar articles

Cited by 4 PubMed Central articles

References

    1. Kuipers EJ, Thijs JC, Festen HP. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther. 1995;9( Suppl 2):59–69. - PubMed
    1. Kurata JH, Nogawa AN. Meta-analysis of risk factors for peptic ulcer: nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking. J Clin Gastroenterol. 1997;24:2–17. doi: 10.1097/00004836-199701000-00002. - DOI - PubMed
    1. Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology. 1996;110:1244–1252. doi: 10.1053/gast.1996.v110.pm8613015. - DOI - PubMed
    1. Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol. 2004;99:1833–1855. doi: 10.1111/j.1572-0241.2004.40014.x. - DOI - PubMed
    1. Aalykke C, Lauritsen K. Epidemiology of NSAID-related gastroduodenal mucosal injury. Best Pract Res Clin Gastroenterol. 2001;15:705–722. doi: 10.1053/bega.2001.0230. - DOI - PubMed

Publication types

MeSH terms

Substances

Feedback